Eli Lilly and Co. (LLY) today reported positive results from a phase 3 trial of Jaypirca in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), dubbed BRUIN CLL-322.
The BRUIN CLL-322 trial has two study arms - Jaypirca plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients did not take any CLL therapy until their disease progressed.
According to the results, the study met its primary endpoint, demonstrating that the addition of Jaypirca to venetoclax plus rituximab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS).
Overall survival (OS), an important secondary endpoint, is not yet fully established, but early results suggest a positive trend for the Jaypirca combination regimen.
Jaypirca is already approved for use in the treatment of mantle cell lymphoma (MCL), and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
Detailed results from the study are expected to be shared later this year.
LLY closed Friday at $939.46, down 1.65%. In the premarket trade, shares are trading at $935.62, down 0.41%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.